Topic: Eisai Co. Ltd.

Eslicarbazepine acetate

Mahalo - 474 days ago
Eslicarbazepine acetate ( BIA 2-093 ) is an antiepileptic drug. Exalief and will be marketed as Zebinix or Exalief by Eisai Co. Pharmaceutical Business Review:

Adjunctive Drug Helpful in Controlling Epileptic Seizures

Modern Medicine - 506 days ago
Patients taking rufinamide in addition to their regular antiepileptic medication experience a significant reduction in total partial seizures, according to research published online Sept. 30 in Epilepsia. Adverse events, which included dizziness, fatigue, nausea, somnolence, and diplopia, occurred at an incident rate ...

FDA Approves Banzel (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder

Drugs.com - 1191 days ago
Eisai Corporation of North America announced today that the U.S. Food and Drug Administration (FDA) approved Banzel (rufinamide) for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children 4 years and older and adults. Eisai received a complete response ...

Eisai Submits New Drug Application to the FDA for Anti-epileptic Drug Rufinamide

Drugs.com - 1192 days ago
Ridgefield Park, President Mindell Seidlin, M.D.) has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the anti-epileptic drug (AED) rufinamide. Eisai is seeking approval for two indications for rufinamide, as adjunctive therapy for Lennox-Gastaut syndrome ...

Eisai Resubmits NDA for the Anti-epilepsy Drug Rufinamide

Drugs.com - 1192 days ago
Mindell Seidlin), a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. , announced today that they resubmitted the New Drug Application (NDA) for the anti-epilepsy agent rufinamide on Nov. 16, 2005. Eisai Medical Research had withdrawn the original NDA in early November and ...

Status of the E2007 (perampanel) Development Program

Drugs.com - 1412 days ago
Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications - E2007 (perampanel) is a first-in-class, orally administered, highly selective non-competitive AMPA-type glutamate receptor antagonist, in development by Eisai for several indications, including Parkinson's disease, neuropathic pain, epilepsy, ...